These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 26991772)

  • 1. Vascular Effects of Eplerenone in Coronary Artery Disease With Preserved Ejection Fraction: A Double-Blind, Randomized, Placebo-Controlled Trial.
    Sudano I; Naegele M; Roas S; Périat D; Frank M; Kouroedov A; Noll G; Lüscher TF; Enseleit F; Ruschitzka F; Flammer AJ
    Clin Cardiol; 2016 May; 39(5):285-90. PubMed ID: 26991772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction.
    Udelson JE; Feldman AM; Greenberg B; Pitt B; Mukherjee R; Solomon HA; Konstam MA
    Circ Heart Fail; 2010 May; 3(3):347-53. PubMed ID: 20299607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
    Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
    Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction.
    Serenelli M; Jackson A; Dewan P; Jhund PS; Petrie MC; Rossignol P; Campo G; Pitt B; Zannad F; Ferreira JP; McMurray JJV
    JACC Heart Fail; 2020 Mar; 8(3):188-198. PubMed ID: 31926854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effectiveness of Eplerenone vs Spironolactone on Left Ventricular Systolic Function, Hospitalization and Cardiovascular Death in Patients With Chronic Heart Failure-HFrEF.
    Naser N; Durak-Nalbantic A; Sabanovic-Bajramovic N; Karic A
    Med Arch; 2023 Apr; 77(2):105-111. PubMed ID: 37260796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension.
    White WB; Carr AA; Krause S; Jordan R; Roniker B; Oigman W
    Am J Cardiol; 2003 Jul; 92(1):38-42. PubMed ID: 12842242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aldosterone inhibition and coronary endothelial function in women without obstructive coronary artery disease: an ancillary study of the national heart, lung, and blood institute-sponsored women's ischemia syndrome evaluation.
    Bavry AA; Handberg EM; Huo T; Lerman A; Quyyumi AA; Shufelt C; Sharaf B; Merz CN; Cooper-DeHoff RM; Sopko G; Pepine CJ
    Am Heart J; 2014 Jun; 167(6):826-32. PubMed ID: 24890531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of mineralocorticoid receptor antagonists on cardiac function in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials.
    Kapelios CJ; Murrow JR; Nührenberg TG; Montoro Lopez MN
    Heart Fail Rev; 2019 May; 24(3):367-377. PubMed ID: 30618017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: a systematic review and network meta-analysis of 32 randomized trials.
    Pamporis K; Karakasis P; Sagris M; Zarifis I; Bougioukas KI; Pagkalidou E; Milaras N; Samaras A; Theofilis P; Fragakis N; Tousoulis D; Xanthos T; Giannakoulas G
    Curr Probl Cardiol; 2024 Jul; 49(7):102615. PubMed ID: 38692445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction.
    Rossignol P; Claggett BL; Liu J; Vardeny O; Pitt B; Zannad F; Solomon S
    Am J Hypertens; 2018 Mar; 31(4):407-414. PubMed ID: 29228101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
    Pitt B; Remme W; Zannad F; Neaton J; Martinez F; Roniker B; Bittman R; Hurley S; Kleiman J; Gatlin M;
    N Engl J Med; 2003 Apr; 348(14):1309-21. PubMed ID: 12668699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eplerenone in patients with systolic heart failure and mild symptoms.
    Zannad F; McMurray JJ; Krum H; van Veldhuisen DJ; Swedberg K; Shi H; Vincent J; Pocock SJ; Pitt B;
    N Engl J Med; 2011 Jan; 364(1):11-21. PubMed ID: 21073363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: results from the EPATH randomized, placebo-controlled trial.
    Tomaschitz A; Verheyen N; Meinitzer A; Pieske B; Belyavskiy E; Brussee H; Haas J; März W; Pieske-Kraigher E; Verheyen S; Ofner-Ziegenfuss L; Hartaigh BÓ; Schwetz V; Aberer F; Grübler M; Lang F; Alesutan I; Voelkl J; Gaksch M; Horina JH; Dimai HP; Rus-Machan J; Stiegler C; Ritz E; Fahrleitner-Pammer A; Pilz S
    J Hypertens; 2016 Jul; 34(7):1347-56. PubMed ID: 27065001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study.
    Chin KL; Collier TJ; Pitt B; McMurray JJ; Swedberg K; van Veldhuisen DJ; Pocock SJ; Vincent J; Turgonyi E; Zannad F; Krum H;
    Eur J Heart Fail; 2016 Sep; 18(9):1175-81. PubMed ID: 26833642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
    J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.
    Epstein M; Williams GH; Weinberger M; Lewin A; Krause S; Mukherjee R; Patni R; Beckerman B
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):940-51. PubMed ID: 17699311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stabilization of Early Duchenne Cardiomyopathy With Aldosterone Inhibition: Results of the Multicenter AIDMD Trial.
    Raman SV; Hor KN; Mazur W; Cardona A; He X; Halnon N; Markham L; Soslow JH; Puchalski MD; Auerbach SR; Truong U; Smart S; McCarthy B; Saeed IM; Statland JM; Kissel JT; Cripe LH
    J Am Heart Assoc; 2019 Oct; 8(19):e013501. PubMed ID: 31549577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale and Design of the Double-Blind, Randomized, Placebo-Controlled Multicenter Trial on Efficacy of Early Initiation of Eplerenone Treatment in Patients with Acute Heart Failure (EARLIER).
    Asakura M; Yamamoto H; Asai K; Hanatani A; Hirata K; Hirayakma A; Kimura K; Kobayashi Y; Momomura S; Nakagawa Y; Nishi Y; Saito Y; Satoh Y; Yamada T; Yamashina A; Yasuda S; Yoshikawa T; Kada A; Uesaka H; Kitakaze M;
    Cardiovasc Drugs Ther; 2015 Apr; 29(2):179-85. PubMed ID: 25566817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MRAs in Elderly HF Patients: Individual Patient-Data Meta-Analysis of RALES, EMPHASIS-HF, and TOPCAT.
    Ferreira JP; Rossello X; Eschalier R; McMurray JJV; Pocock S; Girerd N; Rossignol P; Pitt B; Zannad F
    JACC Heart Fail; 2019 Dec; 7(12):1012-1021. PubMed ID: 31779922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension.
    Karns AD; Bral JM; Hartman D; Peppard T; Schumacher C
    J Clin Hypertens (Greenwich); 2013 Mar; 15(3):186-92. PubMed ID: 23458591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.